PH27150A - Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties - Google Patents
Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties Download PDFInfo
- Publication number
- PH27150A PH27150A PH38540A PH38540A PH27150A PH 27150 A PH27150 A PH 27150A PH 38540 A PH38540 A PH 38540A PH 38540 A PH38540 A PH 38540A PH 27150 A PH27150 A PH 27150A
- Authority
- PH
- Philippines
- Prior art keywords
- metoprolol
- core
- cellulose
- tablet
- salt
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 10
- 230000003204 osmotic effect Effects 0.000 title abstract description 7
- 239000012528 membrane Substances 0.000 title description 21
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960002237 metoprolol Drugs 0.000 claims abstract description 26
- 239000011248 coating agent Substances 0.000 claims abstract description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 229920002678 cellulose Polymers 0.000 claims description 19
- 239000001913 cellulose Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 8
- BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical group OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229960002005 metoprolol fumarate Drugs 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 241001508691 Martes zibellina Species 0.000 claims description 2
- -1 hydroxypropylmethyl Chemical group 0.000 claims description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 241001233887 Ania Species 0.000 claims 1
- 101100298995 Arabidopsis thaliana PBC1 gene Proteins 0.000 claims 1
- 241000209761 Avena Species 0.000 claims 1
- 235000007319 Avena orientalis Nutrition 0.000 claims 1
- 101100205847 Mus musculus Srst gene Proteins 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 235000017276 Salvia Nutrition 0.000 claims 1
- 241001072909 Salvia Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- BBXRRTJNJCPGBU-UHFFFAOYSA-N beta-naphthyl N-acetylphenylalaninate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=O)C(NC(=O)C)CC1=CC=CC=C1 BBXRRTJNJCPGBU-UHFFFAOYSA-N 0.000 claims 1
- 101150010415 eat-5 gene Proteins 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 235000020129 lassi Nutrition 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 210000004916 vomit Anatomy 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract description 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 17
- 239000011230 binding agent Substances 0.000 description 15
- 235000010980 cellulose Nutrition 0.000 description 14
- 229940081735 acetylcellulose Drugs 0.000 description 12
- 229920002301 cellulose acetate Polymers 0.000 description 11
- 239000000463 material Substances 0.000 description 8
- 229940022663 acetate Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 241000518994 Conta Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960001300 metoprolol tartrate Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- CBICCXFXCXELAR-UHFFFAOYSA-N acetic acid;ethyl hydrogen carbonate Chemical compound CC(O)=O.CCOC(O)=O CBICCXFXCXELAR-UHFFFAOYSA-N 0.000 description 1
- ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 1
- MFOPEVCFSVUADB-UHFFFAOYSA-N acetic acid;methyl carbamate Chemical compound CC(O)=O.COC(N)=O MFOPEVCFSVUADB-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- External Artificial Organs (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
- Confectionery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/185,564 US4892739A (en) | 1988-04-25 | 1988-04-25 | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH27150A true PH27150A (en) | 1993-04-02 |
Family
ID=22681522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH38540A PH27150A (en) | 1988-04-25 | 1989-04-20 | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4892739A (cs) |
| EP (1) | EP0339506B1 (cs) |
| JP (1) | JP2750150B2 (cs) |
| KR (1) | KR0125935B1 (cs) |
| AT (1) | ATE75939T1 (cs) |
| AU (1) | AU618083B2 (cs) |
| CA (1) | CA1334382C (cs) |
| DD (1) | DD288093A5 (cs) |
| DE (1) | DE58901373D1 (cs) |
| DK (1) | DK175232B1 (cs) |
| ES (1) | ES2031302T3 (cs) |
| FI (1) | FI90203C (cs) |
| GR (1) | GR3005399T3 (cs) |
| HU (1) | HU201469B (cs) |
| IE (1) | IE61223B1 (cs) |
| IL (1) | IL90019A (cs) |
| MX (1) | MX15754A (cs) |
| NO (1) | NO175186C (cs) |
| NZ (1) | NZ228845A (cs) |
| PH (1) | PH27150A (cs) |
| PT (1) | PT90341B (cs) |
| ZA (1) | ZA892998B (cs) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023076A (en) * | 1987-02-27 | 1991-06-11 | Alza Corporation | Lamina comprising carboxyvinyl polymer |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US5232705A (en) * | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US6764697B1 (en) | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
| EP0621032B1 (en) * | 1993-04-23 | 2000-08-09 | Novartis AG | Controlled release drug delivery device |
| US8524277B2 (en) * | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
| US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| SE0003125D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Modified polymers |
| JP2004531463A (ja) | 2000-11-03 | 2004-10-14 | アンドルクス ラブス，エルエルシー | 徐放メトホルミン組成物 |
| US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
| US20060034922A1 (en) * | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
| US6790459B1 (en) | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
| US6610326B2 (en) | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| EP1411901B1 (en) * | 2001-07-04 | 2010-08-18 | Sun Pharma Advanced Research Company Ltd | Gastric retention controlled drug delivery system |
| GB2384986B (en) * | 2002-02-12 | 2004-01-07 | Reckitt Benckiser Healthcare | Compositions for the treatment of disorders of the upper gastrointestinal tract |
| AU2003241537A1 (en) * | 2002-05-23 | 2003-12-12 | Andrx Corporation | Biguanide formulations |
| JP4694841B2 (ja) | 2002-09-20 | 2011-06-08 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 |
| US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
| US20050048119A1 (en) * | 2002-09-20 | 2005-03-03 | Avinash Nangia | Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
| AU2003903507A0 (en) * | 2003-07-08 | 2003-07-24 | U. S. Filter Wastewater Group, Inc. | Membrane post-treatment |
| US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
| US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| BRPI0507439A (pt) * | 2004-03-05 | 2007-07-03 | Mcneil Ppc Inc | composições poliméricas e formas de dosagem compreendendo as mesmas |
| US20050196448A1 (en) * | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
| US20050196442A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| US20050196447A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| US20050287185A1 (en) * | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
| EP1773477B1 (en) * | 2004-07-05 | 2011-09-07 | Siemens Water Technologies Corp. | Hydrophilic membranes |
| IL166114A0 (en) * | 2005-01-03 | 2006-01-15 | Calcident Active Ltd | Long-acting controlled-release pharmaceutical preparation for use in the oral cavity |
| CN102670555A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 富马酸美托洛尔渗透泵控释片 |
| CN102670539A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 琥珀酸美托洛尔渗透泵控释片 |
| KR20150054918A (ko) | 2012-09-14 | 2015-05-20 | 에보쿠아 워터 테크놀로지스 엘엘씨 | 막을 위한 중합체 블렌드 |
| CA2936746C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US10322375B2 (en) | 2015-07-14 | 2019-06-18 | Evoqua Water Technologies Llc | Aeration device for filtration system |
| WO2020020790A1 (de) * | 2018-07-24 | 2020-01-30 | Bayer Aktiengesellschaft | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| EP4213761A4 (en) * | 2020-09-15 | 2024-12-11 | SynAgile Corporation | DEVICES AND METHODS FOR CONTINUOUS EXTRUSION OF A DRUG INTO THE MOUTH |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4439195A (en) * | 1980-10-14 | 1984-03-27 | Alza Corporation | Theophylline therapy |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
| US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
| US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
| US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| AU571312B2 (en) * | 1984-02-10 | 1988-04-14 | Nycomed Danmark A/S | Diffusion coated multiple-units dosage form |
| US4693886A (en) * | 1985-04-22 | 1987-09-15 | Alza Corporation | Osmotic device with inert core |
| US4609374A (en) * | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
| SE455836B (sv) * | 1985-10-11 | 1988-08-15 | Haessle Ab | Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning |
| EP0271438B1 (de) * | 1986-11-14 | 1992-04-29 | Ciba-Geigy Ag | Orales osmotisches System für Metoprolol mit verbesserten Formulierungseigenschaften |
-
1988
- 1988-04-25 US US07/185,564 patent/US4892739A/en not_active Expired - Lifetime
-
1989
- 1989-04-11 AU AU32687/89A patent/AU618083B2/en not_active Expired
- 1989-04-18 IL IL9001989A patent/IL90019A/en unknown
- 1989-04-20 PH PH38540A patent/PH27150A/en unknown
- 1989-04-21 DE DE8989107213T patent/DE58901373D1/de not_active Expired - Lifetime
- 1989-04-21 PT PT90341A patent/PT90341B/pt not_active IP Right Cessation
- 1989-04-21 AT AT89107213T patent/ATE75939T1/de not_active IP Right Cessation
- 1989-04-21 NZ NZ228845A patent/NZ228845A/xx unknown
- 1989-04-21 FI FI891921A patent/FI90203C/fi not_active IP Right Cessation
- 1989-04-21 MX MX1575489A patent/MX15754A/es unknown
- 1989-04-21 CA CA000597406A patent/CA1334382C/en not_active Expired - Lifetime
- 1989-04-21 EP EP89107213A patent/EP0339506B1/de not_active Expired - Lifetime
- 1989-04-21 ES ES198989107213T patent/ES2031302T3/es not_active Expired - Lifetime
- 1989-04-21 DD DD89327857A patent/DD288093A5/de not_active IP Right Cessation
- 1989-04-24 ZA ZA892998A patent/ZA892998B/xx unknown
- 1989-04-24 JP JP1101829A patent/JP2750150B2/ja not_active Expired - Lifetime
- 1989-04-24 KR KR1019890005342A patent/KR0125935B1/ko not_active Expired - Lifetime
- 1989-04-24 NO NO891680A patent/NO175186C/no not_active IP Right Cessation
- 1989-04-24 HU HU891961A patent/HU201469B/hu unknown
- 1989-04-24 IE IE131689A patent/IE61223B1/en not_active IP Right Cessation
- 1989-04-24 DK DK198901961A patent/DK175232B1/da not_active IP Right Cessation
-
1992
- 1992-08-11 GR GR920401014T patent/GR3005399T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH27150A (en) | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties | |
| CA1339079C (en) | Controlled release device with an impermeable coating having an orifice for release of drug | |
| US6881420B2 (en) | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation | |
| KR0137731B1 (ko) | 방출 지연성 투여형 약물 | |
| EP0664118B1 (en) | Sustained-release tablet | |
| US5229131A (en) | Pulsatile drug delivery system | |
| US5178868A (en) | Dosage form | |
| CA1303502C (en) | Sustained release pharmaceutical compositions in oral dosage form | |
| CA2112679C (en) | Dosage form for delivering drug in short-time period | |
| US4789549A (en) | Sustained release dosage forms | |
| CA2290531A1 (en) | Pharmaceutical formulation of omeprazole | |
| WO2002070021A1 (en) | Gastric delivery of antineoplastic agents and methods of treatment via inhibition of cancer cell using them | |
| CA2346988A1 (en) | Pharmaceutical formulation comprising omeprazole | |
| UA34458C2 (uk) | Дифузійно-осмотична фармацевтична система з регульованим виділенням ліків (варіанти) | |
| RU99126869A (ru) | Фармацевтический препарат омепразола | |
| IE62597B1 (en) | Oral osmotic device for delivering nicotine | |
| HK123394A (en) | Novel dosage form | |
| US20050186273A1 (en) | Controlled release dosage form including a banded engine | |
| US5545442A (en) | Method for using a radiation cured drug release controlling membrane | |
| JP2005533084A (ja) | 液体の有効成分の製剤を含んでなりかつ膨張可能な浸透圧組成物によりその放出を制御する経口の投薬形態 | |
| US20030219485A1 (en) | Oral osmotic controlled drug delivery system | |
| DK175608B1 (da) | Hidtil ukendt doseringsform | |
| CN1859897A (zh) | 用于液态活性剂制剂控制释放的抗渗透的渗透装置和剂型 | |
| US20040062799A1 (en) | Therapeutic composition and delivery system for administering drug |